156 related articles for article (PubMed ID: 28713374)
21. Oncogenic signaling of class I PI3K isoforms.
Denley A; Kang S; Karst U; Vogt PK
Oncogene; 2008 Apr; 27(18):2561-74. PubMed ID: 17998941
[TBL] [Abstract][Full Text] [Related]
22. Phosphoinositide 3-kinase p110 delta regulates natural antibody production, marginal zone and B-1 B cell function, and autoantibody responses.
Durand CA; Hartvigsen K; Fogelstrand L; Kim S; Iritani S; Vanhaesebroeck B; Witztum JL; Puri KD; Gold MR
J Immunol; 2009 Nov; 183(9):5673-84. PubMed ID: 19843950
[TBL] [Abstract][Full Text] [Related]
23. Cutting edge: differential roles for phosphoinositide 3-kinases, p110gamma and p110delta, in lymphocyte chemotaxis and homing.
Reif K; Okkenhaug K; Sasaki T; Penninger JM; Vanhaesebroeck B; Cyster JG
J Immunol; 2004 Aug; 173(4):2236-40. PubMed ID: 15294934
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of class I phosphoinositide 3-kinase activity impairs proliferation and triggers apoptosis in acute promyelocytic leukemia without affecting atra-induced differentiation.
Billottet C; Banerjee L; Vanhaesebroeck B; Khwaja A
Cancer Res; 2009 Feb; 69(3):1027-36. PubMed ID: 19176369
[TBL] [Abstract][Full Text] [Related]
25. Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice.
Okkenhaug K; Bilancio A; Farjot G; Priddle H; Sancho S; Peskett E; Pearce W; Meek SE; Salpekar A; Waterfield MD; Smith AJ; Vanhaesebroeck B
Science; 2002 Aug; 297(5583):1031-4. PubMed ID: 12130661
[TBL] [Abstract][Full Text] [Related]
26. Class IA Phosphatidylinositol 3-Kinase Isoform p110α Mediates Vascular Remodeling.
Vantler M; Jesus J; Leppänen O; Scherner M; Berghausen EM; Mustafov L; Chen X; Kramer T; Zierden M; Gerhardt M; Ten Freyhaus H; Blaschke F; Sterner-Kock A; Baldus S; Zhao JJ; Rosenkranz S
Arterioscler Thromb Vasc Biol; 2015 Jun; 35(6):1434-44. PubMed ID: 25908763
[TBL] [Abstract][Full Text] [Related]
27. High levels of p110δ PI3K expression in solid tumor cells suppress PTEN activity, generating cellular sensitivity to p110δ inhibitors through PTEN activation.
Tzenaki N; Andreou M; Stratigi K; Vergetaki A; Makrigiannakis A; Vanhaesebroeck B; Papakonstanti EA
FASEB J; 2012 Jun; 26(6):2498-508. PubMed ID: 22391131
[TBL] [Abstract][Full Text] [Related]
28. Targeting the phosphoinositide 3-kinase isoform p110delta impairs growth and survival in neuroblastoma cells.
Boller D; Schramm A; Doepfner KT; Shalaby T; von Bueren AO; Eggert A; Grotzer MA; Arcaro A
Clin Cancer Res; 2008 Feb; 14(4):1172-81. PubMed ID: 18281552
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of phosphatidylinositol-3 kinase inhibitors with diverse isoform selectivity profiles for inhibiting the survival of chronic lymphocytic leukemia cells.
Göckeritz E; Kerwien S; Baumann M; Wigger M; Vondey V; Neumann L; Landwehr T; Wendtner CM; Klein C; Liu N; Hallek M; Frenzel LP; Krause G
Int J Cancer; 2015 Nov; 137(9):2234-42. PubMed ID: 25912635
[TBL] [Abstract][Full Text] [Related]
30. Attenuation of phosphoinositide 3-kinase δ signaling restrains autoimmune disease.
Maxwell MJ; Tsantikos E; Kong AM; Vanhaesebroeck B; Tarlinton DM; Hibbs ML
J Autoimmun; 2012 Jun; 38(4):381-91. PubMed ID: 22537464
[TBL] [Abstract][Full Text] [Related]
31. Interleukin 13 increases contractility of murine tracheal smooth muscle by a phosphoinositide 3-kinase p110delta-dependent mechanism.
Farghaly HS; Blagbrough IS; Medina-Tato DA; Watson ML
Mol Pharmacol; 2008 May; 73(5):1530-7. PubMed ID: 18276774
[TBL] [Abstract][Full Text] [Related]
32. Taking PI3Kδ and PI3Kγ one step ahead: dual active PI3Kδ/γ inhibitors for the treatment of immune-mediated inflammatory diseases.
Rommel C
Curr Top Microbiol Immunol; 2010; 346():279-99. PubMed ID: 20593311
[TBL] [Abstract][Full Text] [Related]
33. p110δ PI3K as a therapeutic target of solid tumours.
Xenou L; Papakonstanti EA
Clin Sci (Lond); 2020 Jun; 134(12):1377-1397. PubMed ID: 32556179
[TBL] [Abstract][Full Text] [Related]
34. Functional impact and molecular binding modes of drugs that target the PI3K isoform p110δ.
Hassenrück F; Farina-Morillas M; Neumann L; Landini F; Blakemore SJ; Rabipour M; Alvarez-Idaboy JR; Pallasch CP; Hallek M; Rebollido-Rios R; Krause G
Commun Biol; 2023 Jun; 6(1):603. PubMed ID: 37277510
[TBL] [Abstract][Full Text] [Related]
35. Potency and pharmacokinetics of broad spectrum and isoform-specific p110γ and δ inhibitors in cancers.
Setti A; Kumar MJ; Babu KR; Rasagna A; Prasanna MG; Devi TA; Pawar SC
J Recept Signal Transduct Res; 2016; 36(1):26-36. PubMed ID: 26791581
[TBL] [Abstract][Full Text] [Related]
36. PI3K signalling in B- and T-lymphocytes: new developments and therapeutic advances.
So L; Fruman DA
Biochem J; 2012 Mar; 442(3):465-81. PubMed ID: 22364281
[TBL] [Abstract][Full Text] [Related]
37. Isoform-selective induction of human p110δ PI3K expression by TNFα: identification of a new and inducible PIK3CD promoter.
Whitehead MA; Bombardieri M; Pitzalis C; Vanhaesebroeck B
Biochem J; 2012 May; 443(3):857-67. PubMed ID: 22375552
[TBL] [Abstract][Full Text] [Related]
38. PI3K-δ and PI3K-γ inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models.
Winkler DG; Faia KL; DiNitto JP; Ali JA; White KF; Brophy EE; Pink MM; Proctor JL; Lussier J; Martin CM; Hoyt JG; Tillotson B; Murphy EL; Lim AR; Thomas BD; Macdougall JR; Ren P; Liu Y; Li LS; Jessen KA; Fritz CC; Dunbar JL; Porter JR; Rommel C; Palombella VJ; Changelian PS; Kutok JL
Chem Biol; 2013 Nov; 20(11):1364-74. PubMed ID: 24211136
[TBL] [Abstract][Full Text] [Related]
39. The catalytic phosphoinositol 3-kinase isoform p110δ is required for glioma cell migration and invasion.
Luk SK; Piekorz RP; Nürnberg B; Tony To SS
Eur J Cancer; 2012 Jan; 48(1):149-57. PubMed ID: 22079609
[TBL] [Abstract][Full Text] [Related]
40. Cutting edge: T cell development requires the combined activities of the p110gamma and p110delta catalytic isoforms of phosphatidylinositol 3-kinase.
Webb LM; Vigorito E; Wymann MP; Hirsch E; Turner M
J Immunol; 2005 Sep; 175(5):2783-7. PubMed ID: 16116162
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
